• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

Humana, Novo Nordisk partner for diabetes care

Article

Humana Inc. and Novo Nordisk have announced a 1-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes.

Humana Inc. and Novo Nordisk have announced a 1-year partnership aimed at identifying ways to improve the care and treatment of patients with diabetes. The companies say they will bring together researchers to study the treatment and progression of the disease in an effort to further enhance the health and well-being of people with diabetes.

Nearly 26 million Americans have diabetes, according to the Centers for Disease Control and Prevention, and 7 million remain undiagnosed. Another 79 million Americans have pre-diabetes. The companies project that more Americans will develop diabetes as the population increasingly ages and grows more sedentary and overweight.

"This research collaboration is an important step in the fight against a disease that affects one out of every four Medicare members at Humana," said William Fleming, PharmD, President of Humana Pharmacy Solutions. "We are excited about working together with Novo Nordisk as we will meaningfully advance care and improve the lives of our members."

Related Content
© 2024 MJH Life Sciences

All rights reserved.